0001493152-26-021637
SEC filingRevenue grew 27% YoY on TLANDO royalties, but operating losses widened 84% as R&D spending increased, highlighting the pre-revenue biotech's cash burn challenge.
Revenue for the three months ended March 31, 2026 was $119.4K, compared to $93.9K in the same period of 2025, representing a 27.2% increase. The revenue was entirely from one major customer, Verity Pharma, under the TLANDO license and supply agreement. The increase reflects higher royalty payments and a non-refundable payment for TLANDO product inventory. The company is eligible for additional payments upon marketing authorization and achievement of sales milestones, and will supply TLANDO to SPC at a specified supply price.
Net cash used in operating activities was -$2.3M for Q1 2026, compared to -$2.0M in the prior year period. The company has historically funded operations through equity offerings, debt, and out-licensing. Management believes that existing cash and cash equivalents, along with expected revenues from TLANDO, are sufficient to fund projected operating requirements through at least May 7, 2027. However, the company will need to raise additional capital through equity or debt markets or via out-licensing activities to support its operations beyond that date. If unable to raise additional capital, the company may need to reduce expenses to extend its ability to continue as a going concern.
The most significant event post-quarter was the April 2026 announcement that LPCN 1154 failed to meet its primary endpoint in a Phase 3 trial for postpartum depression. While the drug was well-tolerated, the lack of statistical significance versus placebo raises questions about the development path. Management plans to submit a validation study protocol based on post-hoc analysis of patients with a history of psychiatric conditions, and has requested breakthrough therapy and fast track designations. The outcome introduces uncertainty around future R&D spending, partnership potential, and capital requirements. The company continues to explore partnerships for LPCN 1154 and other pipeline assets, but no agreements have been signed.
The company has incurred significant operating losses in most years since inception and anticipates continued losses for the foreseeable future. These losses have had and will continue to have an adverse effect on stockholders' equity. While management believes current liquidity is adequate through May 2027, the need for additional capital and the risk of going concern persist. The company's ability to continue as a going concern is dependent on its ability to raise capital and generate revenue from its pipeline and partnerships.